IBB Stock News 228.30 05/18/2014 18:20:37 Nasdaq Biotechnology

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 228.30 $IBB

iShares Nasdaq Biotechnology Index Fund (IBB) : Short Sell @ $226.44
Trading Central - Thu May 15, 10:33AM CDT
From a technical view, the ETF is shaping a symmetrical triangle calling for the continuation of the previous bearish trend. Regarding technical indicators, the daily MACD is facing a strong resistance area while the daily RSI is reversing down from...

R.I.P. the Momentum Trade, 2012-2014
at The Street - Tue May 13, 1:39PM CDT
The momentum trade is dead. And a new momentum trade has risen to take its place.

iShares Nasdaq Biotechnology Index Fund (IBB) : Close former position at last price ($232.50)
Trading Central - Tue May 13, 9:10AM CDT
On a relative basis against the IVV S&P500, the iShares Nasdaq Biotechnology Index Fund is losing upward momentum since it is reversing down from a bearish trend line; we prefer to close our long position opened on April 22nd. Trading strategy: ...

Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 2.42% Yesterday
Comtex SmarTrend(R) - Mon May 12, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $227.09 to a high of $232.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $231.14 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.42% Rise
Comtex SmarTrend(R) - Mon May 12, 4:03PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $227.09 to a high of $232.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $231.14 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Growth Correction Over - Real Time Insight
Kevin Cook - Zacks Investment Research - Mon May 12, 2:00PM CDT
Where are you finding GARP now?

Market Bulls Gather for Investors Rotating Portfolios
at The Street - Mon May 12, 12:04PM CDT
Despite all the recent divergences, the market is setting up for a bullish week.

Premier Biomedical Advances Technology via Partnerships
ACCESSWIRE - Fri May 09, 9:28AM CDT
Whitefish, MT / May 9, 2014 / Biotechnology stocks have had a rough quarter, with the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) falling more than 6% since February. Investors have started to re-evaluate the sector's lofty valuations, while higher interest rates in the near future could slow the M&A frenzy. As a result, investors may want to shift their attention to high-growth bargains in the industry.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.82%
Comtex SmarTrend(R) - Thu May 08, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $222.87 to a high of $231.14. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $223.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

After Yesterday's Decline of 1.82%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 08, 3:49PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $222.87 to a high of $231.14. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $223.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon May 05, 1:49AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day

'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.

Pharma ETFs: A Safe Haven from the Biotech Stock Slump? - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Apr 28, 10:42AM CDT
Why investors may want to think about a play on the pharmaceutical ETFs if they want drug industry exposure.

iShares Nasdaq Biotechnology Index Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 2.46% Loss
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation    is the second-largest component of the  iShares Nasdaq Biotech Index  . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...

Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:00AM CDT
Solid results from Gilead, but poor results from Amgen, look to have a big impact on these health care ETFs.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 86

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 81

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 61

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 103

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 33

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 115

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 86

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 113

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 76

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading

Top 5 Most Recently Viewed Articles

SerpApi Reduces AI Token Use with Markdown Output

Updated Category News Views 80

A Big Leap for AI in Data Efficiency Well, here we are watching yet another tech company changing the game—or trying to, at least. SerpApi is shaking things up by announcing a new Markdown output feature, geared specifically toward AI developers. This is some impressive magic where structured search data gets spoon-fed to large language models (LLMs) in a format that's...

Continue Reading
Callinex Mines Reports Promising Exploration at Pine Bay

Updated Category News Views 195

Exploring New Horizons: Callinex Mines' Latest Discoveries Callinex Mines Inc. (TSXV: CNX) recently shared exciting updates from its exploration activities at the Pine Bay Camp, located in the Flin Flon Mining District. The drilling program has uncovered significant mineralization, particularly at the new Blueberry target area. Key Highlights from the Recent Drilling...

Continue Reading
Investor Concerns Grow Over Construction Partners, Inc. Shares

Updated Category News Views 136

Investor Concerns Grow Over Construction Partners, Inc. Shares Pomerantz LLP is currently examining claims on behalf of investors of Construction Partners, Inc. (NYSE: ROAD). This investigation aims to clarify whether the company’s management may have engaged in unlawful business practices or misrepresentation of its financial state. Understanding the Allegations Recent...

Continue Reading
Salesforce Earnings: Navigating Current Market Challenges

Updated Category News Views 75

Salesforce Stock Insights Amid Market Challenges Salesforce (NYSE: CRM) is facing notable resistance in its stock price, indicating potential difficulties in achieving new highs soon. While the recent Q2 results were encouraging, showcasing improved guidance, the market continues to grapple with various challenges. Issues such as slowing growth, macroeconomic pressures,...

Continue Reading
Investors Concerned About Synopsys, Inc. and Possible Losses

Updated Category News Views 147

Investigation into Synopsys, Inc. (SNPS) In recent times, Synopsys, Inc. has been under scrutiny for potential violations of federal securities laws. This investigation is particularly significant for the investors of Synopsys, Inc., commonly referred to as Synopsys. Understanding What Happened On September 9, 2025, Synopsys unveiled its financial results for the third...

Continue Reading